Aza-benzothiophene compounds as STING agonists

US11702430B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Michael D. Altman · Cambridge, US
• Brandon D. Cash · Framingham, US
• Jared N. Cumming · Garwood, US
• Duane DeMong · Somerville, US
• Andrew M. Haidle · Cambridge, US
• James P. Jewell · Jersey City, US
• Matthew A. Larsen · Dedham, US
• Min Lu · San Diego, US
• Ryan D. Otte · Natick, US
• Brandon M. Taoka · Brookline, US
• Benjamin Wesley Trotter · Medfield, US
• Quang T. Truong · Morganville, US

Key dates

• Filing date: Mar 28, 2019
• Grant date: Jul 18, 2023
• Expiry date: May 7, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R5, R6, R8, R9, A, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.